Trevor James
Cuba has developed a therapeutic vaccine for non-small-cell lung cancer (NSCLC) called CIMAvax-EGF. This vaccine was developed by the Center of Molecular Immunology in Havana, Cuba, and was made available to the Cuban population in 2011. Since then, it has been used to treat thousands of patients in Cuba and other countries. CIMAvax-EGF is composed of recombinant human epidermal growth factor (EGF) conjugated to a protein carrier. The vaccine works by manipulating the patient's immune response to produce antibodies against the EGF protein, thereby neutralizing it and depriving cancer cells of a key growth factor. This approach is known as immunotherapy and has been effective in treating various types of cancers, including lung cancer.
| Characteristics | Values |
|---|---|
| Vaccine Name | CIMAvax-EGF |
| Type of Cancer | Non-small-cell lung cancer (NSCLC) |
| Type of Vaccine | Active immunotherapy |
| Mechanism of Action | Blocking epidermal growth factor (EGF) to prevent cancer cell growth |
| Availability | Cuba, Belarus, Colombia, Bosnia and Herzegovina, Peru, Paraguay |
| Side Effects | Chills, fever, feeling sick |
| Cost | Approximately USD $1 per shot to manufacture |
| Clinical Trials | Phase III completed in 2016, Phase IV completed in 2017 |
| US Availability | Limited clinical trials at Roswell Park Comprehensive Cancer Center, Buffalo, NY |
Explore related products
What You'll Learn
- CIMAvax-EGF is a vaccine used to treat non-small-cell lung cancer (NSCLC)
- It was developed by the Center of Molecular Immunology in Havana, Cuba
- The vaccine is available in Cuba and a few other countries
- Roswell Park Comprehensive Cancer Center in Buffalo, New York, is the only US facility offering the treatment
- The vaccine is relatively cheap to produce and store, and has low toxicity
CIMAvax-EGF is a vaccine used to treat non-small-cell lung cancer (NSCLC)
Cuba has developed a vaccine, CIMAvax-EGF, to treat non-small-cell lung cancer (NSCLC). This vaccine is a form of immunotherapy that works by manipulating the patient's immune response to produce antibodies that block a type of protein called epidermal growth factor (EGF), which cancer cells need to grow. By preventing EGF from attaching to its receptor, CIMAvax-EGF starves cancer cells, depriving them of the growth stimulus they require.
CIMAvax-EGF is composed of recombinant human EGF conjugated to a protein carrier, with Montanide ISA 51 used as an adjuvant to enhance the immune response. The vaccine was developed by the Center of Molecular Immunology in Havana, Cuba, and was made available to the Cuban population in 2011. It has since been used to treat thousands of patients in Cuba and other countries. The vaccine is relatively inexpensive to produce and store, costing approximately $1 per shot, and has mild side effects, including chills, fever, and nausea.
While CIMAvax-EGF has shown promising results, it is not yet widely available outside of Cuba due to the United States embargo. However, some cancer patients from the US have defied the embargo and travelled to Cuba for treatment. Roswell Park Comprehensive Cancer Center in Buffalo, New York, became the first American research centre to sponsor a clinical trial with a Cuban-made drug in 2016, marking a historic collaboration between Cuban and American scientists. There are also agreements in place to test CIMAvax-EGF in other countries, including the United States, Japan, and some European nations.
The development of CIMAvax-EGF highlights Cuba's innovative approach to cancer treatment, particularly in the field of immunotherapy. Despite facing obstacles such as limited access to modern medical technology, Cuban scientists have made significant advancements that offer hope for cancer patients worldwide.
Country Thunder: Vaccinated or Not?
You may want to see also
Explore related products
It was developed by the Center of Molecular Immunology in Havana, Cuba
Cuba has developed a vaccine for non-small-cell lung cancer (NSCLC), a cancer that represents the leading cause of cancer-related deaths for both men and women in the country. The vaccine, called CIMAvax-EGF, was developed by the Center of Molecular Immunology (CIM) in Havana, Cuba, and was made available to the Cuban population in 2011. It is currently accessible in Cuba, Belarus, Colombia, Bosnia and Herzegovina, Peru, and Paraguay.
CIMAvax-EGF is a therapeutic vaccine that works by blocking a type of protein called the epidermal growth factor (EGF), which cancer cells need to grow. The vaccine does not directly kill cancer cells but instead starves them by preventing EGF from attaching to its receptor (EGFR) on the cell. This connection is necessary for the cell to proliferate, and without it, the cancer cell dies. CIMAvax-EGF achieves this by manipulating the patient's immune response. It contains a carrier protein that triggers the immune system to produce antibodies against the EGF protein, thereby neutralizing it and depleting its availability in the blood. This, in turn, deprives the cancer cells of the growth stimulus they require.
The development of CIMAvax-EGF is a significant advancement in cancer treatment, and it has attracted international attention. Roswell Park Comprehensive Cancer Center in Buffalo, New York, became the first American research center to sponsor a clinical trial with a Cuban-made drug in 2016, marking a historic collaboration between Cuban and American scientists. The Roswell Park Alliance Foundation has committed $4 million in donor funds to support the initial clinical trials of CIMAvax-EGF.
Despite the United States embargo against Cuba, some American cancer patients have chosen to defy the embargo and travel to Cuba to seek treatment with CIMAvax-EGF. The vaccine is not yet approved for use in the United States, but clinical trials are being organized. The low cost of producing and storing CIMAvax-EGF, at approximately USD $1 per shot, along with its low toxicity and mild side effects, make it a promising treatment option for lung cancer.
New Orleans: Vaccination Requirements for Visitors
You may want to see also
Explore related products
$19.99
The vaccine is available in Cuba and a few other countries
Cuba has developed a therapeutic anticancer vaccine called CIMAvax-EGF for adult patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). The vaccine is based on active immunotherapy, which manipulates an individual's immune response to release antibodies against the epidermal growth factor (EGF). This factor is hijacked by many types of cancer, including cancers of the lung, colon, kidney, and head and neck.
CIMAvax-EGF is composed of recombinant human epidermal growth factor (EGF) conjugated to a protein carrier. It was developed by the Center of Molecular Immunology in Havana, Cuba, and was made available to the Cuban population in 2011. The vaccine is currently available in Cuba, Belarus, Colombia, Bosnia and Herzegovina, Peru, and Paraguay. There are also agreements in place to test it in the United States, Japan, and some European countries.
The Roswell Park Comprehensive Cancer Center in Buffalo, New York, is the first American research centre to sponsor a clinical trial with a Cuban-made drug, marking a historic collaboration between Cuban and American scientists. The centre is currently the only facility in the United States that offers this groundbreaking treatment. While the vaccine is not yet available to the general public in the United States, eligible patients accepted into Roswell Park's clinical trial can access it.
Cuba's progress in cancer vaccine development is notable, especially considering the country's economic isolation and lack of access to modern medical technology. The collaboration between Cuban and American scientists is a positive step towards making groundbreaking cancer treatments more accessible globally.
California's Push for Mandatory Adult Vaccination
You may want to see also
Explore related products
Roswell Park Comprehensive Cancer Center in Buffalo, New York, is the only US facility offering the treatment
Cuba has developed a lung cancer vaccine called CIMAvax-EGF, which is available to its citizens. The vaccine is designed to treat non-small-cell lung cancer (NSCLC) and is currently licensed in Cuba for use in adult patients with stage IIIB/IV of the disease. It works by manipulating the patient's immune response to produce antibodies that target and block a protein called epidermal growth factor (EGF), which cancer cells need to grow.
Due to the United States embargo against Cuba, US citizens are forbidden from seeking medical treatment in Cuba. However, some cancer patients have defied the embargo and travelled to Cuba for treatment with CIMAvax. In recognition of the potential of this vaccine, the Roswell Park Comprehensive Cancer Center in Buffalo, New York, became the first American research centre to sponsor a clinical trial with a Cuban-made drug in 2016. Roswell Park is currently the only US facility with clearance from the US Food and Drug Administration (FDA) to conduct clinical trials with this immunotherapy. The centre is helping to develop several innovative and potentially life-saving cancer therapies through a historic partnership with Cuba's Centro de Inmunología Molecular (CIM).
The Roswell Park Alliance Foundation has committed $4 million in donor dollars to cover the cost of the initial clinical trials, with the goal of bringing this therapy to patients as quickly as possible. CIMAvax is currently available in the US only to eligible patients accepted into Roswell Park's clinical trial, which requires participants to be in Buffalo, New York, for an extended period. This trial is testing CIMAvax-EGF as a potential preventive measure against lung cancer in high-risk individuals or to prevent the recurrence of the disease.
While CIMAvax-EGF is not yet approved for general use in the US, the collaboration between Roswell Park and CIM marks a significant step forward in making this groundbreaking treatment accessible to American patients.
Autism and Vaccines: Uncovering the Link
You may want to see also
Explore related products
The vaccine is relatively cheap to produce and store, and has low toxicity
Cuba has developed a vaccine for non-small-cell lung cancer (NSCLC) called CIMAvax-EGF. This vaccine is composed of recombinant human epidermal growth factor (EGF) conjugated to a protein carrier. The EGF is chemically linked to the Neisseria meningitidis outer protein P64k for immunogenicity.
CIMAvax is relatively cheap to produce and store, and has low toxicity. It costs approximately $1 per shot to manufacture. Side effects of the vaccine appear to be mild, and include chills, fever, and nausea.
The vaccine was developed by the Center of Molecular Immunology in Havana, Cuba, and made available to the Cuban population in 2011. It is currently available in Cuba, Belarus, Colombia, Bosnia and Herzegovina, Peru, and Paraguay. In October 2015, Serbia's Institute of Virology, Vaccines, and Sera (also known as the Torlak Institute) signed a memorandum to use CIMAvax on 30 patients as part of a study.
The development of CIMAvax is a significant achievement, especially considering the limited access to modern medical technology in Cuba. The vaccine has shown promising results, with some American patients even defying the US embargo to seek treatment in Cuba. Clinical trials are also being organized in the United States, the European Union, and Japan.
Vaccine Coverage: What Medicare Part B Offers
You may want to see also
Frequently asked questions
Yes, Cuba has developed a vaccine for non-small-cell lung cancer (NSCLC) called CIMAvax-EGF.
CIMAvax-EGF is an active vaccine that raises antibodies targeting the epidermal growth factor (EGF). This blocks the EGF from attaching to its receptor (EGFR) on the cancer cell, depriving it of the growth stimulus it requires.
CIMAvax-EGF is currently available in Cuba, Belarus, Colombia, Bosnia and Herzegovina, Peru, and Paraguay. It is also being tested in the United States, Japan, and some European countries.
The side effects of the vaccine are mild and may include chills, fever, and nausea.
The vaccine is relatively inexpensive to produce, with a cost of approximately USD $1 per shot. However, the cost of treatment may vary depending on the patient's location and other factors.
